NCT00776516已完成1 期
A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Assess pharmacokinetics of mirabegron alone and in combination with rifampin
研究概览
简要总结
The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.
详细描述
A single group of patients will receive both mirabegron alone and in combination with rifampin
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Weighs at least 45 kg and body mass index (BMI) between 18 and 32 kg/m2 at Screening
- •Normal or not clinically significant 12 lead ECG and clinical laboratory test results at Screening
- •Female subjects must be post-menopausal, surgically sterile since at least 1 month prior to screening, or practicing effective non-hormonal contraceptive methods. All females must be non-lactating, and should have a negative result for the pregnancy test at Screening and on Day -1
- •Negative drug and alcohol screens
排除标准
- •Has known or suspected hypersensitivity to mirabegron or rifampin
- •Liver enzyme test abnormalities (ALT, AST, or bilirubin) above the upper limit of normal
- •History or presence of psychiatric illness, serious active or recurrent infection or hepatitis
- •Previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years prior to the dose of study drug
- •Donation or loss of ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
- •Received or is anticipated to receive a prescription drug within 14 days prior to Day -1 or within 30 days prior to Day -1 for any long acting treatments. Use of any over-the-counter medications, including complementary and alternative medicines (except for occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days prior to Day -1
- •History of substance abuse within 6 months prior to Screening
- •Current participation in another clinical trial or is taking or has been taking an investigational drug in the 30 days or 10 half lives of the drug, whichever is longer, prior to dosing
- •Known to have hepatitis or HIV-1 and/or HIV-2 or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at Screening
- •Subject has consumed alcohol, caffeine-containing food or beverages, grapefruit juice, grapefruit-containing products or Seville oranges within 48 prior to Day -1
研究组 & 干预措施
2
Experimental
mirabegron and rifampin
干预措施: rifampin (Drug)
1
Experimental
mirabegron alone
干预措施: mirabegron (Drug)
2
Experimental
mirabegron and rifampin
干预措施: mirabegron (Drug)
结局指标
主要结局
Assess pharmacokinetics of mirabegron alone and in combination with rifampin
时间窗: One month
次要结局
- Assess safety and tolerability of mirabegron alone and in combination with rifampin(one month)
研究者
相似试验
已完成
1 期
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy SubjectsChronic Hepatitis CHepatitis CNCT01646489Santaris Pharma A/S5
已完成
1 期
A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy SubjectsCystic FibrosisNCT03516331Flatley Discovery Lab LLC16
已完成
1 期
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy AdultsPainNCT06392659Vertex Pharmaceuticals Incorporated42
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese ParticipantsHealthy VolunteersNCT04497883Shire24
已完成
1 期
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsDrug Interaction StudyNCT02807051CTI BioPharma20